SCHEMBL10194690

SCHEMBL10194690

Fc1ccc2c(-c3cn(-c4ccc(CN5CCCCC56COC6)cc4)nn3)n[nH]c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
CHEK1 O14757 4/20 0.34
CDK7 P50613 4/20 0.34
HTR2A P28223 2/20 0.33
MCHR1 Q99705 3/20 0.33
MAP2K4 P45985 3/20 0.33
MAPK1 P28482 2/20 0.33
MAPKAPK2 P49137 1/20 0.33
MAPKAPK3 Q16644 1/20 0.33
MAPK6 Q16659 1/20 0.33
KCNH2 Q12809 1/20 0.33
NTRK1 P04629 1/20 0.32
CDC7 O00311 1/20 0.32
ROCK2 O75116 1/20 0.32
MAP4K4 O95819 1/20 0.32
PIM1 P11309 1/20 0.32
CDK2 P24941 1/20 0.32
HIPK2 Q9H2X6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10194978 0.90 CHEK1 (0.35) CHEK1CDK7MCHR1KCNH2CDC7
SCHEMBL10194685 0.76 LRRK2 (0.36) CHEK1CDK7HTR2AMAP2K4MAPK1
SCHEMBL10194689 0.75 S1PR1 (0.38) FGFR1FLT1KDRMAP2K4MAPK1
SCHEMBL10194762 0.71 ABL1 (0.45) MAP2K4MAPK1MAPK6NTRK1FLT3
SCHEMBL10195053 0.70 STAT3 (0.44) FGFR1FLT1CHEK1CDK7MAP2K4
SCHEMBL10194977 0.70 FGFR1 (0.45) FGFR1FLT1CHEK1CDK7KCNH2
SCHEMBL10194983 0.69 P2RY14 (0.47) HTR2AMAP2K4SIGMAR1
SCHEMBL10194970 0.68 JAK2 (0.47) FGFR1FLT1NTRK1CDC7ROCK2
SCHEMBL10194743 0.67 P2RY14 (0.39) FGFR1FLT1KDRHTR2ASIGMAR1
SCHEMBL10194779 0.67 CDC7 (0.44) FGFR1FLT1CHEK1CDK7MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES NFATC1, IL5, CD4 FGFR1 3392/4885FLT1 1926/4885KDR 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.